Related Experiment Video

Updated: May 12, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Antiangiogenic therapies for advanced hepatocellular carcinoma

Keeran R Sampat1, Bert O'Neil

  • 1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

The Oncologist
|April 12, 2013
PubMed

Insights

Hepatocellular carcinoma (HCC) treatment is advancing with targeted therapies. Sorafenib, a multikinase inhibitor, improves survival in advanced HCC by blocking vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling pathways.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • HCC tumors are highly vascular, driven by proangiogenic factors like vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).
  • Sorafenib, a multikinase inhibitor, was the first systemic treatment to improve survival in advanced HCC by targeting VEGF and PDGF signaling.

Purpose of the Study:

  • To review current clinical and preclinical data on HCC systemic therapies.
  • To discuss the role of anti-angiogenic therapies, including VEGF inhibitors, in HCC treatment.
  • To explore strategies for overcoming resistance to anti-VEGF therapies by targeting alternative proangiogenic pathways.

Main Methods:

  • Review of recent clinical trial data.
  • Analysis of preclinical research findings.
  • Evaluation of ongoing studies in HCC therapy.

Main Results:

  • Sorafenib demonstrates improved survival in advanced HCC patients.
  • Several novel VEGF-targeting drugs are under development.
  • Research is exploring combination therapies to address potential resistance to anti-VEGF treatments.

Conclusions:

  • Targeting VEGF and PDGF pathways with agents like sorafenib is a key strategy in advanced HCC.
  • Anticipation of therapeutic resistance necessitates the investigation of drugs targeting alternative proangiogenic pathways.
  • Ongoing research focuses on developing novel agents and combination strategies to improve HCC patient outcomes.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...